Skip to main content
Fig. 1 | BMC Pulmonary Medicine

Fig. 1

From: Temporal echocardiographic assessment of pulmonary hypertension in idiopathic pulmonary fibrosis patients treated with nintedanib with or without oxygen therapy

Fig. 1

Patient flow diagrams of nintedanib prospective and historical control studies. a In the nintedanib prospective study, 31 consecutive idiopathic pulmonary fibrosis (IPF) patients were enrolled. Fifteen patients failed to continue nintedanib treatment for 48 weeks for various reasons (adverse events, n = 6; death, n = 6; lost to follow-up, n = 3). Follow-up studies were available in 16 patients at 48 weeks. b In the historical control study, 35 consecutive IPF patients were screened retrospectively. Of these patients, 20 IPF patients were excluded for some reason (poor quality echocardiography, n = 8; treated with anti-fibrotic therapy, n = 12). Finally, 15 IPF patients who did not receive any anti-fibrotic therapies were analyzed

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us